Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KB 707

Next Previous
Drug Profile

KB 707

Alternative Names: KB-707

Latest Information Update: 07 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Krystal Biotech
  • Class Antineoplastics; Gene therapies; Immunotherapies
  • Mechanism of Action Gene transference; Immunologic cytotoxicity; Interleukin 12 replacements; Interleukin 2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Lung cancer; Solid tumours

Most Recent Events

  • 03 Nov 2025 Krystal Biotech plans a registrational phase III trial for Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in second half of 2026
  • 02 Sep 2025 Phase-I/II clinical trials in Lung cancer (Late-stage disease, Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (Inhalation) (NCT06228326)
  • 21 Aug 2025 Krystal Biotech expects End of Phase II meeting with the US FDA to discuss potential development pathways to support the registration of inhaled KB707 in October 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top